Grand Pharmaceutical Group's low P/E ratio reflects its poor earnings outlook. Investors foresee limited growth, hence the reduced stock price. The share price is unlikely to see a significant rise soon.
The falling share price of Grand Pharmaceutical Group doesn't align with its EPS growth. This suggests EPS may not truly reflect company performance or past growth expectations were too high.
远大医药股票讨论区
暂无评论